Related Experiment Videos
The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes
Tumelo Mashishi1, Clive M Gray
1AIDS Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa.
Clinical Chemistry and Laboratory Medicine
|November 19, 2002
Summary
The ELISPOT assay quantifies HIV-specific T lymphocytes by detecting cytokine secretion. This sensitive method is crucial for evaluating vaccines and therapies against viral pathogens.
Area of Science:
- Immunology
- Virology
- Vaccinology
Background:
- Characterizing human leukocyte antigen (HLA) class I restricted epitopes from viral pathogens is vital for therapeutic interventions and vaccine development.
- Sensitive, cost-effective assays are needed to measure antigen-specific T lymphocytes for vaccine and therapy evaluation.
Purpose of the Study:
- To review the ELISPOT technique for quantifying HIV-specific T lymphocytes.
- To discuss the standardization and international application of ELISPOT in clinical trials.
Main Methods:
- Review of the ELISPOT (Enzyme-Linked ImmunoSpot) technique.
- Detection of antigen-induced cytokine secretion from T lymphocytes in peripheral blood at a single-cell level.
Main Results:
- The ELISPOT assay successfully quantifies T cell immune responses to various pathogens.
- It can assess T cell immunogenicity of vaccines in clinical trials (Phase I/II/III).
Conclusions:
- ELISPOT is a valuable tool for quantifying viral-specific T lymphocytes.
- Standardization can enable its use across multiple international clinical trial sites for vaccine and therapy monitoring.